Apatinib is a targeted drug with better effect in treating advanced gastric cancer, and patients with effective treatment can significantly prolong their survival time. Apatinib is a targeted drug to inhibit tumor neoangiogenesis, single agent for patients with advanced gastric adenocarcinoma or gastro-esophageal junction adenocarcinoma that has progressed or recurred after receiving at least 2 previous systemic chemotherapies, and the patients should be in good general condition when receiving the treatment. Patients do not need to undergo genetic testing before using the drug, and clinical studies have confirmed that it can prolong the overall survival time of gastric cancer patients by about 1.8 months. The drug can cause various side effects such as high blood pressure, bleeding, proteinuria, and diarrhea. It should be contraindicated for those who are allergic to any components of the drug; for patients with active bleeding, ulcers, intestinal perforation, intestinal obstruction, within 30 days after major surgery, high blood pressure uncontrollable by the drug, grade 3-4 cardiac insufficiency, and severe hepatic and renal insufficiency. Drugs should be used under the guidance of a doctor, regular review during the use of medication, if there is any discomfort promptly consult a doctor to avoid delays in the condition.